Omeros Corporation - Common Stock (OMER)

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels.

In today's session, these stocks are experiencing unusual volume.

Unusual volume stocks are being observed in Thursday's session.

Find out if the deal Omeros announced is enough of a reason to buy this stock.

The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart.

Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31.

In a dramatic turn of events that sent shockwaves through the biotechnology sector, Omeros Corporation (NASDAQ: OMER) witnessed its stock catapult by an astounding nearly 150% after announcing a colossal licensing agreement with pharmaceutical titan Novo Nordisk (CPH: NOVO B). The deal, potentially valued at up to $2.1 billion,

Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties.

Novo Nordisk is licensing exclusive global rights to the company's experimental treatment for rare blood and kidney diseases.

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Omeros Corp (OMER) reports Q2 2025 with narrowed losses, progress on narsoplimab FDA approval, and strategic debt restructuring. Shares rise on regulatory optimism.

The application includes outcomes from more than 130 patients treated under an expanded access program, supporting broader regulatory momentum for narsoplimab.

H.C. Wainwright's Brandon Folkes initiated Omeros with a Buy.